CFH and hemolytic-uremic syndrome: Dysregulation of the alternative pathway of complement (APC) or the coagulation system due to genetic mutations or acquired antibodies, primarily to complement factor H (CFH), increases the risk of HUS, commonly referred to as “atypical” (aHUS) [2, 8].